BRIEF published on 04/01/2026 at 18:05, 1 month 21 days ago EXACOMPTA CLAIREFONTAINE annonce des résultats financiers en baisse pour 2025 Résultats Financiers Baisse Des Revenus Marché De La Papeterie Perspectives 2026 Segment Papier
BRIEF published on 04/01/2026 at 18:05, 1 month 21 days ago EXACOMPTA CLAIREFONTAINE Reports Decline in 2025 Financial Results Financial Results Revenue Decline Stationery Market 2026 Outlook Paper Segment
REGULATED PRESS RELEASE published on 04/01/2026 at 18:00, 1 month 21 days ago Financial statements - 31 december 2025 EXACOMPTA CLAIREFONTAINE Board of Directors reviewed and approved 2025 financial statements, highlighting revenue and operating income figures. Economic conditions and outlook also discussed Financial Statements Revenue Operating Income Exacompta Clairefontaine Economic Conditions
BRIEF published on 03/26/2026 at 18:05, 1 month 27 days ago EXACOMPTA CLAIREFONTAINE : Bilan 2025 et Prévisions pour 2026 Chiffre D'affaires Résultat Opérationnel Marché Papeterie Coûts Énergétiques Perspectives 2026
BRIEF published on 03/26/2026 at 18:05, 1 month 27 days ago EXACOMPTA CLAIREFONTAINE: 2025 Review and 2026 Forecast Revenue Stationery Market Energy Costs Outlook 2026 Operational Result
REGULATED PRESS RELEASE published on 03/26/2026 at 18:00, 1 month 27 days ago Arrêté des comptes au 31 décembre 2025 et perspectives 2026 Résumé des résultats financiers et perspectives d'Exacompta Clairefontaine pour 2025 et 2026 Résultats Financiers Assemblée Générale Dividende Perspectives Exacompta Clairefontaine
BRIEF published on 01/07/2026 at 18:05, 4 months 15 days ago Exacompta Clairefontaine: Voting Rights and Shares in 2025 Share Capital Voting Rights Actions Exacompta Clairefontaine Self-monitoring
BRIEF published on 01/07/2026 at 18:05, 4 months 15 days ago Exacompta Clairefontaine : Droits de Vote et Actions en 2025 Droits De Vote Capital Social Actions Exacompta Clairefontaine Autocontrôle
REGULATED PRESS RELEASE published on 01/07/2026 at 18:00, 4 months 15 days ago Droits de vote et actions 2025 Déclaration du nombre total de droits de vote et d'actions composant le capital de la société EXACOMPTA CLAIREFONTAINE au cours de l'année 2025 Capital Déclaration Droits De Vote Actions Exacompta Clairefontaine
REGULATED PRESS RELEASE published on 10/01/2025 at 18:15, 7 months 21 days ago Financial statements - 30 june 2025
Published on 05/23/2026 at 03:15, 14 hours 15 minutes ago UraniumX Approved for Trading on the OTCQB Venture Market and Announces Board Change
Published on 05/23/2026 at 03:00, 14 hours 30 minutes ago Battery X Metals Reports Up to ~84 km Estimated Driving Range Increase Across Multiple BYD Electric Vehicles Following Next-Generation Patent-Pending Lithium-Ion Battery Rebalancing Trials, Demonstrating Performance Improvement Across the World’s Larges
Published on 05/23/2026 at 02:25, 15 hours 5 minutes ago Battery X Metals Announces up to $2 Million Private Placement Financing and Initiative to Strengthen Balance Sheet
Published on 05/23/2026 at 02:25, 15 hours 5 minutes ago Bolt Metals Completes 402 line-km MobileMT Survey at Northwind Property, Quebec
Published on 05/23/2026 at 01:00, 16 hours 30 minutes ago LIR Life Sciences Announces Initiation of Phase 1 Macromolecule-Enabled Transdermal Delivery Development with Neuland Laboratories
Published on 05/23/2026 at 16:30, 59 minutes ago HiFS 2026: Upgrading Four Major Digital Finance Solutions to Accelerate Financial Institutions Toward Agentic Banking
Published on 05/23/2026 at 15:57, 1 hour 33 minutes ago EQS-Adhoc: Delivery Hero confirms approach by Uber Technologies’ with respect to potential takeover offer
Published on 05/22/2026 at 22:05, 19 hours 25 minutes ago Abivax présente ses résultats financiers du T1 2026 et les données à trois ans de l’étude 108, un essai d’extension ouvert de phase 2a/2b évaluant l’obéfazimod après réduction de dose dans la RCH
Published on 05/22/2026 at 22:05, 19 hours 25 minutes ago Abivax Presents Q1 2026 Financial Results and Reports Three-Year Interim Data from Study 108, a Phase 2a/2b Open-Label Extension Trial of Obefazimod Following Dose De-Escalation in Patients with UC
Published on 05/22/2026 at 19:51, 21 hours 38 minutes ago Turkiye Garanti Bankasi A.S.: Brokerage Houses Warrants Redemption Prices
Published on 05/22/2026 at 19:35, 21 hours 55 minutes ago PROJET D'EVOLUTION DE SA GOUVERNANCE ET LA NOMINATION D'UN PRESIDENT DU DIRECTOIRE PAR INTERIM
Published on 05/22/2026 at 18:05, 23 hours 24 minutes ago Déclaration hebdomadaire d'opérations effectuées du 18 au 22 mai 2026
Published on 05/22/2026 at 18:05, 23 hours 24 minutes ago Disclosure of transactions in own shares from May 18 to May 22, 2026
Published on 05/22/2026 at 12:52, 1 day 4 hours ago Communiqué du Conseil d’administration – Assemblée Générale du 22 mai 2026
Published on 05/22/2026 at 12:52, 1 day 4 hours ago Release from the Board of Directors - Shareholders’ Meeting of May 22, 2026
